Private Advisory Group LLC Invests $987,000 in United Therapeutics Co. (NASDAQ:UTHR)

Private Advisory Group LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,753 shares of the biotechnology company’s stock, valued at approximately $987,000.

A number of other large investors have also added to or reduced their stakes in UTHR. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 33 shares in the last quarter. Toronto Dominion Bank boosted its position in United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after buying an additional 37 shares during the period. ClariVest Asset Management LLC grew its stake in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after buying an additional 42 shares during the period. Finally, Access Investment Management LLC boosted its holdings in United Therapeutics by 0.8% during the 2nd quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock valued at $2,314,000 after acquiring an additional 55 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. UBS Group lifted their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Wells Fargo & Company upped their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. TD Cowen increased their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, Bank of America reduced their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $357.17.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $328.03, for a total value of $1,180,908.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $42,643.90. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $328.03, for a total transaction of $1,180,908.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $42,643.90. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,238 shares of company stock worth $35,612,493 in the last three months. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Trading Up 1.1 %

UTHR opened at $358.22 on Friday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $366.08. The stock has a market cap of $15.94 billion, a PE ratio of 16.46, a PEG ratio of 1.30 and a beta of 0.57. The business has a 50 day moving average of $346.73 and a 200-day moving average of $303.39.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same quarter last year, the company posted $5.24 EPS. United Therapeutics’s revenue for the quarter was up 19.8% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.